NN-6561 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
NN-6561 is under clinical development by Novo Nordisk and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
NN-6561 is under clinical development by Novo Nordisk and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
What's Your Reaction?
